121 studies found for:    Open Studies | niaid
Show Display Options
Rank Status Study
21 Recruiting Immune Monitoring and CNI Withdrawal in Low Risk Recipients of Kidney Transplantation
Condition: Kidney Transplant
Interventions: Drug: Tacrolimus + MMF + Prednisone, followed by Tacrolimus Withdrawal;   Drug: MMF/Tacrolimus/Prednisone
22 Not yet recruiting A Research Trial of Aralast in New Onset Diabetes (RETAIN) - Part II
Condition: Diabetes Mellitus, Type 1
Interventions: Drug: Alpha 1-Antitrypsin (AAT, Aralast NP);   Drug: Placebo
23 Recruiting Evaluating the Safety and Immune Response to a Single Dose of a Respiratory Syncytial Virus (RSV) Vaccine in RSV-Seronegative Infants and Children
Condition: Respiratory Syncytial Virus Infections
Interventions: Biological: RSV cps2 Vaccine;   Biological: Placebo Vaccine
24 Recruiting Evaluation of the Safety and Immunogenicity of a Live Attenuated Human Metapneumovirus Vaccine
Condition: Metapneumovirus
Interventions: Biological: 10^6 PFU rHMPV-Pa vaccine;   Biological: 10^5 PFU rHMPV-Pa vaccine;   Biological: Placebo Vaccine
25 Recruiting Evaluating Safety and Effectiveness of Low-Dose Methotrexate at Reducing Inflammation in HIV-Infected Adults Taking Antiretroviral Medications
Condition: HIV Infections
Interventions: Drug: Methotrexate (MTX);   Drug: Placebo;   Dietary Supplement: Folic acid
26 Recruiting Randomized MMF Withdrawal in Systemic Lupus Erythematosus (SLE)
Condition: Lupus Erythematosus, Systemic
Interventions: Drug: Mycophenolate Mofetil;   Drug: Hydroxychloroquine or Chloroquine;   Drug: Prednisone
27 Recruiting Safety and Efficacy of Investigational Immune Plasma in Treating Influenza A
Condition: Influenza A
Interventions: Biological: Anti-Influenza Plasma;   Behavioral: Standard Care
28 Unknown  Safety of an Oral HIV Vaccine in HIV Uninfected Volunteers
Condition: HIV Infections
Intervention: Biological: SCBaL/M9
29 Recruiting Trichuris Suis Ova Treatment in Left-sided Ulcerative Colitis
Condition: Colitis, Ulcerative
Interventions: Biological: Trichuris suis ova (TSO);   Biological: Placebo
30 Recruiting Evaluating the Safety and Immune Response to a Single Dose of a Respiratory Syncytial Virus (RSV) Vaccine in Infants and Children
Condition: Respiratory Syncytial Virus Infections
Interventions: Biological: RSV ΔNS2 Δ1313 I1314L Vaccine;   Biological: Placebo (1x Leibovitz L-15 medium)
31 Recruiting T and B Cell Responses Across Autoimmune Diseases
Conditions: Type 1 Diabetes Mellitus;   Multiple Sclerosis;   Arthritis, Rheumatoid;   Crohn Disease;   Psoriasis
Intervention:
32 Recruiting Modeling Study to Predict Progression of Anal Cancer Pre-cursor Lesions in HIV
Conditions: Neoplasms, Squamous Cell;   Papillomavirus Infections
Intervention:
33 Unknown  SCOT Scleroderma Treatment Alternative Registry (STAR Registry)
Conditions: Scleroderma, Systemic;   Sclerosis
Intervention: Behavioral: Telephone Call
34 Recruiting ADRN Barrier/Immunoprofiling Exploratory Pilot Study
Conditions: Dermatitis;   Dermatitis, Atopic
Intervention:
35 Unknown  Study of Chlorhexidine as the Hub Antiseptic to Prevent Catheter Related Infections in Newborn Infants
Condition: Catheterization
Intervention: Device: 3.15% chlorhexidine as daily antiseptic on needleless access port
36 Unknown  Resistance to HIV Infection
Condition: HIV Infections
Intervention:
37 Recruiting Registry for the Atopic Dermatitis Research Network
Conditions: Atopic Dermatitis;   Eczema Herpeticum
Intervention:
38 Recruiting Comparing the Efficacy, Safety, and Tolerability of Combination Antivirals (Amantadine, Ribavirin, Oseltamivir) Versus Oseltamivir for the Treatment of Influenza in Adults at Risk for Complications
Condition: Influenza
Interventions: Drug: Amantadine, Ribavirin, Oseltamivir;   Drug: Oseltamivir
39 Not yet recruiting Evaluating the Safety and Drug Levels of an Antibody Against HIV in Healthy, HIV-Uninfected Adults
Condition: HIV Infections
Interventions: Biological: VRC01;   Biological: SC placebo for VRC01;   Biological: IV placebo for VRC01
40 Recruiting Evaluating the Safety and Immunogenicity of a Live Attenuated West Nile Virus Vaccine for West Nile Encephalitis in Adults 50 to 65 Years of Age
Condition: West Nile Virus
Interventions: Biological: WN/DEN4Δ30 Vaccine;   Biological: Placebo

Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results
Indicates status has not been verified in more than two years